Pharma needs research, not cuts

Ingram Pinn illustration
©Ingram Pinn

If the entire industry adopted Valeant’s approach, drug discovery would grind to a halt

Deals fever grips pharma industry

Day of M&A activity takes transactions for year to $140bn

Allergan hits back in pharma deals frenzy

Botox-maker adopts poison pill defence against $48bn bid

Valeant raises eyebrows with Ackman link

Activist has been rapidly building stake in Botox-maker Allergan

The Joker’s on Quindell

Shares plunge means fat profit for shortseller Gotham City

Witty seeks to overcome difficult year

GSK chief hopes Novartis deal will speed up group’s transformation

GSK not keen to join megamerger mania

Assets swap with Novartis fits trend towards targeted acquisitions

Valeant / Allergan: crow’s feet

A pharma deal with some wrinkles to smooth out to prolong the life of cash flows

GSK / Novartis: big renovation

Asset reshuffle should help both sides

Allergan contests $46bn Valeant bid terms

Shares trade above value of Bill Ackman-backed offer

Eli Lilly: momentum and mean reversion

Delivering growth will not be easy for the US drugmaker

Novartis chief makes biggest move

Ackman in bid for Botox maker Allergan

Activist joins Valeant for $45.6bn cash and stock offer

Saudi health minister removed

Fears that the spread of respiratory virus is accelerating

TPG snaps up Chinese hospital operator

Private healthcare chain Chindex to be acquired for $461m

Pfizer talks boost AstraZeneca shares

Prominent analyst predicts US group will make second attempt

Novartis buys GSK arm in asset swap deal

Pharmaceutical groups will also combine consumer operations

Pfizer / AstraZeneca: combination therapy

Commitment to diverse R&D clashes with cost savings objectives

Big pharma deals are back in the mix

UK’s takeover rules comes under scrutiny

Fears revive that foreign takeovers of groups are too easy


More FT Twitter accounts